Technology evaluation: TroVax, Oxford BioMedica.
TroVax, a gene-based tumor vaccine that uses a poxvirus vector to deliver the tumor antigen gene 5T4, is under development by Oxford BioMedica for the potential treatment of cancer. TroVax is undergoing phase II clinical trials.